GSK/Theravance Begin New Relvar Ellipta Phase III Study In Japan

GlaxoSmithKline and Theravance have begun a Phase III efficacy and safety study of Relvar Ellipta, a combination treatment of the inhaled corticosteroid (ICS), fluticasone furoate; and long-acting beta 2 agonist, vilanterol (FF/VI). The study will evaluate the contribution of the ICS component on lung function, in patients with chronic obstructive pulmonary disease (COPD). Positive results from this study will help support a potential filing of FF/VI for the treatment of patients with COPD in Japan.

This is a 12-week, multicentre, randomised, double-blind, parallel-group study to evaluate the efficacy and safety of FF/VI 100/25mcg once-daily, compared with VI 25mcg once-daily, administered via the GSK's Ellipta inhaler. Patients included in the study will have a history of COPD with at least one exacerbation in the year prior to screening and will demonstrate current symptoms of COPD. The study seeks to enrol approximately 1580 patients from across 250 study centres worldwide, including approximately 350 patients from centres in Japan.

The FF/VI Phase III development programme in patients with COPD contained data from six studies in over 6,000 COPD patients. Specific Japanese patient efficacy data were only available from two six-month efficacy studies. In these studies the contribution of FF 100mcg to the combination, on lung function, did not achieve statistical significance.

GlaxoSmithKline and Theravance have begun a Phase III efficacy and safety study of Relvar Ellipta, a combination treatment of the inhaled corticosteroid (ICS), fluticasone furoate; and long-acting beta 2 agonist, vilanterol (FF/VI). The study will evaluate the contribution of the ICS component on lung function, in patients with chronic obstructive pulmonary disease (COPD). Positive results from this study will help support a potential filing of FF/VI for the treatment of patients with COPD in Japan.

This is a 12-week, multicentre, randomised, double-blind, parallel-group study to evaluate the efficacy and safety of FF/VI 100/25mcg once-daily, compared with VI 25mcg once-daily, administered via the GSK's Ellipta inhaler. Patients included in the study will have a history of COPD with at least one exacerbation in the year prior to screening and will demonstrate current symptoms of COPD. The study seeks to enrol approximately 1580 patients from across 250 study centres worldwide, including approximately 350 patients from centres in Japan.

The FF/VI Phase III development programme in patients with COPD contained data from six studies in over 6,000 COPD patients. Specific Japanese patient efficacy data were only available from two six-month efficacy studies. In these studies the contribution of FF 100mcg to the combination, on lung function, did not achieve statistical significance.

In July 2013, GSK withdrew its FF/VI NDA in Japan for the COPD indication, while designing an additional study, as there were insufficient data to support the efficacy of the combination and its components in this specific patient group. Demonstration of a statistically significant contribution of FF 100mcg to the combination on lung function needs to be shown in this study, with a trend demonstrating a positive benefit in the Japanese patients sub-group, being pivotal for the approval of FF/VI 100/25mcg for treatment of COPD in Japan.

FF/VI strengths of 100/25mcg and 200/25mcg were licensed by the Japanese Ministry of Health, Labour and Welfare for the treatment of asthma under the Relvar Ellipta brandname in September 2013. FF/VI is not licensed in Japan for the treatment of patients with COPD.

This article is tagged to:
Sector: Pharmaceuticals & Healthcare, Medical Devices
Geography: Japan, United Kingdom, United States
×

Enter your details to read the full article

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.